This article was published on July 1, 2025, at 4:37 p.m. on the ChosunBiz MoneyMove site.
Korea's leading umbilical cord blood bank corporation MEDIPOST is seeking to raise around 100 billion won. This is to complete the Phase 3 clinical trial of umbilical cord-derived stem cell therapeutics in the United States.
On the 1st, according to the investment banking (IB) sector, MEDIPOST is currently working to attract investment of around 100 billion won through BDA Partners. It is distributing teaser letters to potential buyers, and it is noted that large venture capital firms with strong financial capabilities are showing interest.
The investment methods and conditions have not yet been determined. However, there is a strong possibility that it will be raised through convertible bonds (CB) in the market.
Considering the overall market capitalization of the company, the scale of this funding is quite significant. Currently, MEDIPOST's market capitalization is approximately 450 billion won. The stock price has risen by about 60% over the past three months. This rise appears to reflect expectations for performance improvement as it actively pursues its cell and gene therapy (CGT) contract development and manufacturing (CDMO) business.
MEDIPOST is a biotechnology corporation founded in 2000 by CEO Yang Yoon-seon, a former professor at Samsung Medical Center. It was listed on the KOSDAQ market in 2005 and has secured a leading position in the field of regenerative medicine by developing 'CATIS', Korea's first stem cell therapeutic. Last year, its revenue was approximately 70.6 billion won.
The largest shareholders of MEDIPOST are private equity fund management firms SkyLake Equity Partners (21.4%) and Crescendo Equity Partners (22.2%). Founder CEO Yang Yoon-seon owns 1.73%.
The reason MEDIPOST is seeking to raise about 100 billion won is to complete the Phase 3 clinical trial of its flagship product, 'CATIS', in the United States.
CATIS is a pharmaceutical composed mainly of mesenchymal stem cells derived from umbilical cord blood. It is a treatment for knee cartilage defects in patients with degenerative or recurrent traumatic osteoarthritis.
In Korea, it has been on sale since receiving product approval from the Ministry of Food and Drug Safety in 2012, but it is still preparing for Phase 3 trials in the United States. The market expects that if CATIS successfully enters the U.S. market, exports to Europe will also become possible.